Sophie Y. Lavergne
Pfizer (United States)(US)
Publications by Year
Research Areas
Receptor Mechanisms and Signaling, Drug Transport and Resistance Mechanisms, Neuropeptides and Animal Physiology, Lipid metabolism and biosynthesis, Diabetes Treatment and Management
Most-Cited Works
- → Synthesis of Sulfones from Organozinc Reagents, DABSO, and Alkyl Halides(2013)152 cited
- → Discovery and Optimization of Imidazopyridine-Based Inhibitors of Diacylglycerol Acyltransferase 2 (DGAT2)(2015)81 cited
- → Identification of Tetrahydropyrido[4,3-d]pyrimidine Amides as a New Class of Orally Bioavailable TGR5 Agonists(2012)47 cited
- → Optimization of triazole-based TGR5 agonists towards orally available agents(2012)31 cited
- → Design and evaluation of a 2-(2,3,6-trifluorophenyl)acetamide derivative as an agonist of the GPR119 receptor(2011)29 cited
- → From partial to full agonism: Identification of a novel 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole as a full agonist of the human GPR119 receptor(2012)21 cited
- Perceval ou le conte du Graal(1997)
- → Optimization of Metabolic and Renal Clearance in a Series of Indole Acid Direct Activators of 5′-Adenosine Monophosphate-Activated Protein Kinase (AMPK)(2018)18 cited
- → Identification of Morpholino-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-ones as Nonsteroidal Mineralocorticoid Antagonists(2018)16 cited
- → Discovery of new piperidine amide triazolobenzodiazepinones as intestinal-selective CCK1 receptor agonists(2012)14 cited